Back

The role of digoxin in atrial fibrillation.

5 April 2022 (08:42 - 08:54)
Organised by:
Congress Presentation Part of: Is there still room for drugs to control atrioventricular nodal conduction in atrial fibrillation (AF)? Atrial Fibrillation (AF) EHRA Premium Access EHRA 2022

About the speaker

Photo
Professor Paulus Kirchhof

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

4 More presentations in this session

Presentation thumbnail
AV nodal blocking therapy in AF: when, how and for whom?
Professor S. Boveda (Toulouse, FR)
Slides Video
Presentation thumbnail
The role of a calcium channel blocker in atrial fibrillation.
Doctor R. Tieleman (Groningen, NL)
Slides Video
Presentation thumbnail
Ablate and pace: the preferred therapy now?
Professor P. Vardas (Heraklion, GR)
Slides Video
Presentation thumbnail
Is there still room for drugs to control AV nodal conduction in AF? - discussion.
Video

Access the full session

Session thumbnail
Is there still room for drugs to control atrioventricular nodal conduction in atrial fibrillation (AF)?
Video

The Event

Event poster

EHRA 2022

5 April 2022 08:42 CET
You may be interested in
thumbnail
Congress Presentation
Rate control first for most atrial fibrillation patients: beta-blocker and/or digitalis?
29 August 2022
thumbnail
Congress Presentation
DIG-META: Digoxin in heart failure and atrial fibrillation
28 August 2023
thumbnail
Congress Presentation
Utilization and safety of digoxin in patients with chronic heart failure and atrial fibrillation with rapid ventricular rate
30 August 2024
thumbnail
Congress Presentation
Digitoxin and digoxin: standard therapy for HFrEF?
9 May 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources